SVB Securities Keeps Their Buy Rating on Halozyme (HALO)
August 17 2022 - 10:36PM
TipRanks
SVB Securities analyst David Risinger maintained a Buy rating on
Halozyme (HALO - Research Report) on August 15 and set a price
target of $52.00. The company's shares closed yesterday at
$43.41.According to TipRanks, Risinger is a 2-star analyst with an
average return of 2.5% and a 55.56% success rate. Risinger covers
the Healthcare sector, focusing on stocks such as Pfizer, Sanofi,
and Eli Lilly & Co.The word on The Street in general, suggests
a Strong Buy analyst consensus rating for Halozyme with a $54.60
average price target, representing a 25.78% upside.
https://www.tipranks.com/news/blurbs/svb-securities-keeps-their-buy-rating-on-halozyme-halo?utm_source=advfn.com&utm_medium=referral
Halozyme Therapeutics (NASDAQ:HALO)
Historical Stock Chart
From Dec 2022 to Jan 2023
Halozyme Therapeutics (NASDAQ:HALO)
Historical Stock Chart
From Jan 2022 to Jan 2023